Leverage our deep scientific expertise in gene expression, editing and delivery to help you accelerate the path to commercialization and bring safer, more effective treatments to patients.
Overview
Our novel licensable technologies complement our preclinical contract services and provide an alternative way to connect scientific teams, not just to deliver insights and data but also to tackle challenges together to enhance therapeutic outcomes.
We've helped bring many therapies to clinical trials and to approval by the relevant regulatory agencies.
For example, Trinomab Biotech implemented our CHOSOURCE™ CHO-K1 knockout cell line in their drug development workflow to produce a monoclonal antibody drug candidate against different diseases, including the first in-human mAb in phase I trial in Australia against tetanus toxin.
We’ve also partnered with AstraZeneca who licensed our Pin-point™ base editing platform to develop universal donor cells which will be used as the foundation for various targeted therapies, such as cell therapies for the treatment of immune-mediated diseases and cancer.
Find out more about our licensable technologies and how we can work together to help unlock your therapy’s potential.
Explore our solutions
Why our partners work with us:
- Advice supported by decades of experience
- Access to industry-leading innovation
- No conflict of interest, such as a competing therapeutic pipeline
- Autonomy to choose your service providers
The Pin-point™ base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity.
LentiBOOST™ GMP Grade: Not for Diagnostic Use. Other applications must be authorized by a license from Revvity. LentiBOOST™ Pharma-Grade: For research use only. Not for use in diagnostic procedures.
The CHOSOURCE™ Platform is available for research, clinical, diagnostic, and commercialization applications, including services, under specific licenses from Revvity.
How can we help you?
We are here to answer your questions.